AEON Biopharma Stock Market Outlook
| AEON Stock | 0.92 0.01 1.00% |
Changes in the tone and volume of recent news coverage can help explain how the market is framing the stock, even when the recommendation label does not change. Around 52% of recent sentiment around AEON Biopharma has been mildly defensive over the recent sample. Taken on its own, that leaves the current sentiment reading for AEON Biopharma close to neutral at this time.
Investor Comfort Level
PanicConfidence
48 · Impartial
Elasticity to Hype and News Sentiment
AEON Biopharma news coverage registers mixed at 50%, a data point that gauges whether public narrative is leading or lagging the business reality. Shifts in news tone at this level often precede a change in trading character that warrants attention.
Given a 90-day horizon, with an above-average risk tolerance, the model output for AEON Biopharma is 'Strong Sell'. The recommendation model incorporates AEON Biopharma's available fundamental, technical, and predictive indicators.
AEON Biopharma |
Run AEON Biopharma Outlook Model
The AEON Biopharma signal is designed to work alongside the professional consensus covering AEON Biopharma. Macroaxis is editorially and financially independent with no stake in AEON Biopharma. AEON Biopharma's outlook reflects a systematic evaluation of price behavior and fundamental quality. Use this alongside your own research for a more complete market view.
How This Model Works
The recommendation output for AEON Biopharma is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am an educated risk taker
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
Strong Sell
Market Performance | Weak | Details | |
Volatility | Abnormal | Details | |
Current Valuation | Above Model Estimate | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Shows low sensitivity to market movements | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
AEON Biopharma's current outlook reflects a cautious setup, where weak recent performance and soft fundamental readings cloud near-term visibility. The model's 'Strong Sell' signal reflects persistent headwinds that outweigh the offsetting factors in the model. Over the selected time horizon, AEON Biopharma shows Mean Deviation of 3.96, Standard Deviation of 5.28, and Variance of 27.86, which weigh on the current risk-reward outlook.AEON Biopharma's analytical framework reflects a quantitative assessment of growth potential, downside exposure, and market positioning relative to the expert outlook. For additional context on this micro-cap stock, analyze the full set of AEON Biopharma reported fundamentals, including the relationship between the number of employees and working capital ttm. As AEON Biopharma appears to be a penny stock, its number of shares shorted numbers are an important reference point for this model output.
Recent Events and Market Context
The events below reflect recent headlines associated with AEON Biopharma. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.
Returns Distribution Density
The chart below shows the full range of AEON Biopharma's daily returns. The chart shows the most common daily returns and how far outliers have reached. Value At Risk measures downside risk while Upside Potential measures the gain side. AEON Biopharma's return distribution chart shows how likely different daily outcomes are for AEON Biopharma.
| Mean Return | -0.12 | Value At Risk | -7.78 | Potential Upside | 7.14 | Standard Deviation | 5.28 |
Return Density |
| Distribution |
Big price swings are rare but central to AEON Biopharma risk assessment. The return distribution chart answers that question at a glance. It quantifies the risk-reward profile of different risk-return profiles. The foundation of risk management is estimating how likely large price swings are.
Key Drivers of Volatility and Market Exposure
AEON Biopharma volatility reflects broader stock market cycles alongside company or sector-specific developments. Diversified portfolios reduce specific exposure but not systemic risk. For AEON Biopharma, recent data highlights a Mean Deviation of 3.96 and a Standard Deviation of 5.28.
α | Alpha over Dow Jones | -0.1262 | |
β | Beta against Dow Jones | -0.4538 | |
σ | Overall volatility | 5.27 | |
Ir | Information ratio | -0.0266 |
Fundamentals Vs Peers
Peer-level comparison for AEON Biopharma tests whether the market's pricing reflects relative fundamental strength or weakness. When AEON Biopharma's ratios diverge materially from peers, the gap signals either a mispricing opportunity or a structural difference worth investigating. The peer context below makes AEON Biopharma's fundamental positioning more precise than standalone analysis allows. AEON Biopharma's competitive position across common fundamental metrics becomes clear from the peer data below.
| Better Than Average | Worse Than Average | Compare AEON Biopharma to competition |
| Fundamentals | AEON Biopharma | Peer Average |
| Return On Asset TTM | -2.34 | -0.14 |
| Current Valuation | 57.73 M | 16.62 billion |
| Shares Outstanding | 26.31 M | 571.82 million |
| Shares Owned By Insiders | 85.36 % | 10.09 % |
| Shares Owned By Institutions | 7.56 % | 39.21 % |
| Number Of Shares Shorted | 103.23 K | 4.71 million |
| Price To Sales TTM | 97.16 X | 11.42 X |
| EBITDA TTM | -16.82 M | 3.9 billion |
| Net Income TTM | -39.22 M | 570.98 million |
| Total Debt TTM | 35.74 M | 5.32 billion |
| Book Value Per Share TTM | -4.54 X | 1,931 |
| Cash Flow From Operations TTM | -17.31 M | 971.22 million |
| Short Ratio TTM | 0.80 X | 4.00 X |
| Earnings Per Share | -3.95 X | 3.12 X |
| Target Price | 6.7 | N/A |
| Number Of Employees | 8 | 18,840 |
| Trailing Beta | 0.66 | -0.15 |
| Market Capitalization TTM | 24.99 M | 19.03 billion |
| Total Asset TTM | 5.56 M | 29.47 billion |
| Retained Earnings TTM | -470.82 M | 9.33 billion |
| Working Capital TTM | -3.5 M | 1.48 billion |
| Net Asset | 5.56 M | N/A |
Note: Acquisition by Jost Fischer of 50000 shares of AEON Biopharma at 0.4988 subject to Rule 16 b-3 [view details]
Market Momentum
With RSI at 45 and beta at -0.4538, AEON Biopharma strength signals show whether demand and trading pressure are supporting or weakening the current setup. Comparing these readings with volume and earnings revisions strengthens the signal since the signal is more company-driven than market-linked.
Recommendation Framework, Assumptions & Editorial Oversight
The model output for AEON Biopharma reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for AEON Biopharma include market cap of 24.99 million. 
AEON Biopharma inputs come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.
Editorial Review & Methodology Oversight
Role: Member of Macroaxis Board of Directors
Finance background: Michael joined Macroaxis in August of 2020 after several months of consulting for the company on financial matters regarding the post-pandemic world and upcoming inflation. In his investing and articles, Michael focuses his analyses on inflation, data processing and its role in AI/ML, FinTech, and the surprising parallels that arise between neurobiology and finance.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.